Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood
The Journal of Infectious Diseases · 17.03.2025 · 231 (3) · 600-610
DOI: 10.1093/infdis/jiae530 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 28.10.2024. Verfasst von Lucía Bailón und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Lamivudine, HIV Infections, HIV-1. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fundació Lluita Contra les Infeccions, NIAID NIH HHS, Wellcome Trust.
Abstract (Originalsprache)
Background
To compare the effects of first-line antiretroviral therapy (ART) with dolutegravir plus lamivudine (DTG + 3TC) versus dolutegravir plus emtricitabine/tenofovir alafenamide (DTG + FTC/TAF) on the human immunodeficiency virus type 1 (HIV-1) reservoir and immune activation biomarkers in people with HIV (PWH).
Methods
DUALITY was a 48-week, single-center, randomized, open-label clinical trial in ART-naive PWH, randomized (1:1) to receive ART with DTG + 3TC (2DR group) or DTG + FTC/TAF (3DR group). We measured total and intact proviral HIV-1 DNA, cell-associated RNA in CD4+ T cells, frequency of HIV-infected CD4+ T cells able to produce p24, plasma soluble inflammatory markers, and activation and exhaustion markers in CD4+ and CD8+ T cells.
Results
Forty-four participants (22 per study arm) were enrolled, with baseline mean (standard deviation) log10 plasma viral load (pVL) 4.4 (0.7) copies/mL and CD4+ T-cell counts of 493 (221) cells/μL. At week 48, all participants had pVL <50 copies/mL at week 48, except for 1 participant in the 2DR group who was resuppressed after treating syphilis. Changes from baseline in reservoir parameters and immune biomarkers were comparable between groups.
Conclusions
First-line ART with DTG + 3TC showed similar reductions of HIV-1 persistence parameters and immune markers as DTG + FTC/TAF, supporting DTG/3TC among preferred first-line ART options for PWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol.
- Fundació Lluita contra les Infeccions.
- Institute for Health Science Research Germans Trias i Pujol, Badalona.
- Centro de Investigación Biomédica en Red Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid.
- IrsiCaixa, Badalona.
- Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Cerdanyola del Vallés.
ORCID-Profile: Igor Moraes-Cardoso, Yovaninna Alarcón-Soto, Elias P Rosen, Jacob D Estes, Alex Olvera, Beatriz Mothe, José Moltó
Förderung
- Fundació Lluita Contra les Infeccions
- NIAID NIH HHS
- Wellcome Trust
- National Institute for Allergy and Infectious Diseases
- ViiV Healthcare
Zitieren
APA
Bailón, L., Puertas, M. C., García-Guerrero, M. C., Moraes-Cardoso, I., Aparicio, E., Alarcón-Soto, Y., Rivero, A., Rosen, E. P., Estes, J. D., Blanco, J., Olvera, A., Mothe, B., Martinez-Picado, J., Moltó, J., & DUALITY Study Group (2025). Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. The Journal of Infectious Diseases, 231(3), 600-610. https://doi.org/10.1093/infdis/jiae530
Vancouver
Bailón L, Puertas MC, García-Guerrero MC, Moraes-Cardoso I, Aparicio E, Alarcón-Soto Y, et al. Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood. The Journal of Infectious Diseases. 2025;231(3):600-610. doi:10.1093/infdis/jiae530
BibTeX
@article{Bailn2025,
author = {Bailón, Lucía and Puertas, Maria C and García-Guerrero, Maria C and Moraes-Cardoso, Igor and Aparicio, Ester and Alarcón-Soto, Yovaninna and Rivero, Angel and Rosen, Elias P and Estes, Jacob D and Blanco, Julià and Olvera, Alex and Mothe, Beatriz and Martinez-Picado, Javier and Moltó, José and DUALITY Study Group, DUALITY Study Group},
title = {Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {231},
number = {3},
pages = {600--610},
doi = {10.1093/infdis/jiae530}
}
EUVIMED